Pre-clinical studies have validated the potential of Hsp90 inhibition in, e.g., suppressing tumor growth and metastatic potential as well as sensitizing tumors to the effect of chemotherapeutic therapies, the latter possibly as a consequence of the inhibition of double strand break (DSB) repair due to the many DNA repair proteins present as Hsp90 clients. The gene discussed is HSP90AB1; the disease is neoplasm.